HOME >> BIOLOGY >> NEWS
Protein essential for making steroids turns out to be a "molten globule"

he body," Miller said. "Hormone replacement therapy can save their lives, but the children also must receive mineralcorticoid and glucocorticoid replacements throughout their lives to help maintain salt and sugar balance."

Miller's lab has been working in cooperation with Michael Baldwin, PhD, and Thomas James, PhD, in the department of pharmaceutical chemistry at UCSF to determine the structure of StAR and learn how it works.

Miller credits Bose, a postdoctoral fellow with a background in physical chemistry, for enlisting help from Baldwin, James and other UCSF experts in protein spectroscopy to study how the StAR protein is folded into its final shape. Most proteins are not active in this incompletely folded state, but Bose concluded that StAR does its work of ushering cholesterol into the mitochondria when it is partially unfolded.

That may be because the ports that allow entry into mitochondria are very small, Bose said. "Think of a protein as a ball of spaghetti. It can only get into the mitochondria one strand at a time." A section of the protein called the "mitochondrial leader" enters a port. Inside the mitochondria, import machinery begins to pull the protein in - as if it were slurping in a strand of spaghetti. StAR unfolds to enter the port, but a compactly folded section of the protein unfolds more slowly and creates a pause in the process.

In their article for The Proceedings of the National Academy of Sciences, Bose, Miller and their colleagues propose that this flexible, "molten globule" conformation lowers the energy required for a channel to open in the mitochondrial membrane. In this form, StAR appears to function as an on/off switch for cholesterol flowing from the cell into the mitochondria. If so, it may be the first protein found that does its work in a molten globule state. More studies are necessary to determine StAR's exact structure and to work out the details of how it shepherds cholesterol into the mitochondria to be
'"/>

Contact: Janet Basu
jbasu@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
22-Jun-1999


Page: 1 2 3

Related biology news :

1. Protein is key to fatal disorder and normal cell function
2. Protein is key for digestive function of the pancreas
3. Proteins show promise for mosquito control
4. Protein involved in childhood disorder linked to cancer
5. Protein fishing in America: The movie
6. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
7. Protein key to trafficking in nerve terminals
8. Protein controls acid in cells by direct detection of volume changes, study finds
9. Protein believed to control formation of memory identified by Scripps & UCSD scientists
10. Protein stops blood-vessel growth, holds promise as cancer therapy
11. Proteins transform DNA into molecular velcro

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Protein essential for making steroids turns out molten globule

(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: